Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Anti-Venom Market size was over USD 733.51 million in 2024 and is projected to reach USD 2.16 billion by 2037, witnessing around 8.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of anti-venom is assessed at USD 787.75 million.
The growth of the market can be attributed to the rising technological innovation in the treatment for venomous bite, along with the increasing investment in development of new drugs. Moreover, the growing incidences of snakebites across the globe, is anticipated to further boost the market growth. According to the data by the World Health Organization (WHO), around 5.4 million people are bitten by snakes each year. Moreover, up to 2.7 million people are envenomed yearly. This has resulted in a very high demand for anti-venoms, which is estimated to drive the anti-venom market growth. Along with this, the government concerns to reduce deaths caused by envenoming, and initiatives to produce novel anti-venoms, are projected to boost the market growth. However, several challenges lie with the production of anti-venoms as several countries around the globe do not have regulatory norms to control and monitor the production of these anti-venoms.
Anti-Venom Sector: Growth Drivers and Challenges
Growth Drivers
-
Rising Awareness about Available Anti-Venoms
-
Growing Investment in Medical R&D Activities
Challenges
-
Complexities During the Manufacturing
-
Lack of Regulatory Norms for Anti-Venom Drug Manufacturing
Anti-Venom Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 733.51 million |
|
Forecast Year Market Size (2037) |
USD 2.16 billion |
|
Regional Scope |
|
Anti-Venom Segmentation
The global anti-venom market is segmented by anti-venom type into polyvalent anti-venom, monovalent anti-venom, and others, out of which, the polyvalent anti-venom segment is anticipated to hold the largest share in the market on account of rising demand for polyvalent anti-venom, as they are more effective in neutralizing the effect of the venom of a broad spectrum of snakes.
Our in-depth analysis of the global market includes the following segments:
|
By Species |
|
|
By Anti-Venom Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAnti-Venom Industry - Regional Synopsis
Asia Pacific industry is expected to account for largest revenue share by 2037, led by growing cases of snakebites, which require anti-venom for treatment. According to the data by the WHO, up to 2 million people are envenomed by snakes each year in Asia. Moreover, the improving healthcare sector is estimated to fuel the market growth. The market in the North America is estimated to gain significant share over the forecast period owing to the presence of major pharmaceutical companies in the region manufacturing anti-venoms. Moreover, the high awareness amongst the people in the region for the availability of such drugs is expected to boost the market growth.
Companies Dominating the Anti-Venom Landscape
- Bharat Serums and Vaccines, Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Haffkine Bio-Pharmaceutical Corporation Limited
- Boston Scientific Corporation
- CSL Limited
- Flynn Pharma Ltd (Micropharm)
- Medtoxin Venom Laboratories LLC
- Merck & Co. Inc.
- Pfizer Inc.
- Rare Disease Therapeutics Inc.
- Amgen Inc.
Recent Developments
-
April, 2021: Rare Disease Therapeutics, Inc. announced the approval from United States (US) Food & Drug Administration (FDA) of a new expanded indication for ANAVIP, an equine-derived antivenin.
Author Credits: Radhika Pawar
- Report ID: 3755
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
